Targeting Oxidized LDL: New CAR-T Therapy Reduces Arterial Plaque by 70%
A preclinical study led by researchers at the University of Pennsylvania has demonstrated that CAR T cell therapy—traditionally a cancer treatment—can be effectively adapted to treat atherosclerosis by targeting inflammation. By engineering regulatory T cells (Tregs) to recognize and suppress oxidized LDL (OxLDL), the specific molecule that drives arterial inflammation, the team achieved a 70% reduction in plaque buildup in mice prone to high cholesterol. Unlike standard CAR T therapies that destroy cells, these engineered Tregs work by dampening the local immune response, offering a potential new therapeutic avenue for heart disease patients who remain at risk despite using cholesterol-lowering medications.
medicalxpress.comCar strategy common heart diseasemedicalxpress.com

